PES Statement Supporting Access to Gender Care The Pediatric Endocrine Society supports a patient and family/caregiver-centered approach to healthcare for…
Read MoreMore Articles
New Meds and Tech from PES Drugs and Therapeutics committee The Omnipod 5 (Insulet Inc) is a hybrid closed-loop system approved by the FDA on January 28, 2022 for use…
Read MoreHistorical Tidbit: A cautionary genetics tidbit Submitted by Walter L. Miller, MD Whole exome sequencing (WES) aims to determine the sequence of all protein-coding segments (‘exons’) in genomic DNA. As…
Read MoreNew Meds and Tech from PES Drugs and Therapeutics committee PES Drug Alert – GnRH agonists On July 1, 2022 the Food and Drug Administration (FDA) announced that a warning…
Read MoreHistory Tidbit: The adjustable micropipette Submitted by Walter Miller In our youth, many of us used glass pipettes to make buffers and other solutions. Following the introduction of the adjustable…
Read MoreKara Beliard, MD I am a 3rd-year Pediatric Endocrinology Fellow at the Kravis Children’s Hospital at Mount Sinai, NYC. My time is shared between patient care and basic science research.…
Read MoreUpdate to the Vosoritide (Voxzogo TM) indication in USA On October 20, 2023 US Food and Drug Administration (FDA) has extended approval of Voxzogo to children with Achondroplasia of all…
Read MoreNew Meds and Tech from PES Drugs and Therapeutics committee SKYTROFA® Anna Ryabets-Lienhard, DO, Christine Yu, MD, Emily Breidbart, MD In August 2021, FDA approved SKYTROFA® (lonapegsomatropin-tcgd), the first…
Read More